Teva Pharmaceuticals USA initiated a voluntary Class II recall for Octreotide Acetate for Injectable Suspension 10mg (single-dose 8mL vials) distributed nationwide. The recall was triggered by quality system deficiencies identified at the contract manufacturer Pharmathen International S.A. in Greece during a routine FDA inspection, raising concerns about sterility assurance of the product.\n\nHealthcare providers and distributors should immediately identify and quarantine any affected product in their inventory and cease administration. Pharmacies and healthcare facilities should notify patients who may have received this medication. The recall is ongoing and no specific return deadline was provided. Adverse reactions or quality problems should be reported to the FDA MedWatch program.